Enlivex stock: DSMB clears continued Phase IIb enrollment
Published on 11/22/2026 at 13:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSClinical Trial Update
- An independent safety board reviewed data from 85 randomized and dosed patients.
- The Phase IIb study is designed to enroll approximately 182 patients across the United States, Denmark and Poland.
- Key efficacy assessments cover pain and physical function at three and six months after treatment.
Enlivex said on November 18, 2026, that an independent Data and Safety Monitoring Board had completed an interim safety review of its Phase IIb Allocetra trial in age-related knee osteoarthritis. The board confirmed that the observed safety profile allows enrollment to continue as planned, according to The Manila Times, which republished the GlobeNewswire release.
Safety Review Keeps Trial Moving
The interim review covered 85 patients who had been randomized and dosed. Enlivex said the trial remains focused on Allocetra, an investigational therapy evaluated through three intra-articular injections in patients aged 64 and older with moderate-to-severe symptomatic primary knee osteoarthritis.
The randomized, double-blind, placebo-controlled study is planned to enroll approximately 182 patients at clinical centers in the United States, Denmark and Poland. Its principal efficacy measures are changes from baseline in pain and physical function versus placebo at three and six months after treatment.
Upcoming Efficacy Milestones
The study also includes quality-of-life measures, functional mobility assessments and a one-year follow-up. The safety decision supports continued enrollment, while future efficacy results remain important for assessing Allocetra's clinical development path.
Enlivex Ltd. Company Facts
- Company: Enlivex Ltd.
- ISIN: IL0011319527
- Ticker: ENLV
- Listing: Nasdaq
- Lead program: Allocetra for age-related knee osteoarthritis
Israel's broader market context is covered in the TA-35 market overview.
